Oramed Pharmaceuticals Inc.
ORMP
$2.74
-$0.01-0.36%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -12.44% | -36.93% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -2.49% | -61.71% | |||
| Operating Income | 2.49% | 44.69% | |||
| Income Before Tax | 352.65% | 286.09% | |||
| Income Tax Expenses | 8,879.37% | -121.58% | |||
| Earnings from Continuing Operations | 264.92% | 273.51% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -78.57% | -- | |||
| Net Income | 264.20% | 273.88% | |||
| EBIT | 2.49% | 44.69% | |||
| EBITDA | 2.56% | 44.99% | |||
| EPS Basic | 264.12% | 271.68% | |||
| Normalized Basic EPS | -0.45% | 57.09% | |||
| EPS Diluted | 264.52% | 263.16% | |||
| Normalized Diluted EPS | 0.45% | 57.85% | |||
| Average Basic Shares Outstanding | 0.03% | 1.25% | |||
| Average Diluted Shares Outstanding | 0.39% | 3.35% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||